Gestala is a Chinese brain-computer interface startup developing non-invasive ultrasound-based neuromodulation technology. Founded in January 2026 by serial entrepreneur Phoenix Peng (co-founder of NeuroXess) and Tianqiao Chen (founder of Shanda Interactive), the company is headquartered in Chengdu with offices in Shanghai and Hong Kong.

The company uses focused ultrasound (FUS) delivered through phased-array transducers to precisely stimulate or suppress neural activity in targeted brain regions without surgical implantation. Unlike electrical BCI systems that record from localized cortical areas, ultrasound can potentially access deep brain structures and broader neural circuits through the intact skull. The technology is bidirectional in ambition: the first-generation device focuses on therapeutic stimulation, with plans to eventually decode brain states by measuring ultrasound-derived changes in cerebral blood flow.

Gestala's initial clinical target is chronic pain management, specifically the anterior cingulate cortex, with early pilot data suggesting single-session pain score reductions lasting up to one week. The company is also researching applications in depression, PTSD, autism, OCD, stroke rehabilitation, and neurodegenerative diseases. Gestala is building an "Ultrasound Brain Bank" clinical dataset to train AI models for brain signal decoding. The company raised $21.6 million in its seed round, the largest early-stage BCI investment in China.